5 results about "Clear cell" patented technology

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

This invention relates to a sample processing reagent and its application in flow cytometry analysis, belonging to the field of flow cytometry analysis technology. The invention provides a sample processing reagent comprising a hemolysin and a cell-permeable agent. The hemolysin comprises tris(hydroxymethyl)aminomethane (Tris), sodium chloride, calcium chloride, disodium ethylenediaminetetraacetate, paraformaldehyde, and a solvent. The cell-permeable agent comprises sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, nonylphenol polyoxyethylene ether, Triton X-100, paraformaldehyde, and a solvent. The hemolysin is mild and highly effective, providing complete hemolysis and clear cell clustering. The cell-permeable agent permeates the cell membrane under isotonic and neutral conditions, minimizing damage to cell surface antigens and effectively detecting both cytoplasmic and nuclear antigens.

The invention belongs to the field of fish immunology, and relates to a rat anti-grass carp CD8 alpha monoclonal antibody capable of identifying grass carp CD8 + T cells, a hybridoma cell strain and application. The CDR sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.1-3, the CDR sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.4-6, and the monoclonal antibody can be secreted by a hybridoma cell strain with the preservation number of CCTCC NO: C2025329. The monoclonal antibody disclosed by the invention can be used for identifying the grass carp CD8 + T cells with high specificity and high sensitivity in a flow cytometry and the like, the cell grouping is obvious, and an important tool is provided for subsequently and deeply developing action mechanism research of the CD8 + T cells in grass carp immune response and grass carp vaccine effect evaluation.

Provided herein is technology for ovarian cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of ovarian cancer and sub-types of ovarian cancer (e.g., clear cell ovarian cancer, endometrioid ovarian cancer, mucinous ovarian cancer, serous ovarian cancer).

This invention discloses the application of reagents for detecting REEP protein in the preparation of products for diagnosing prostate cancer, relating to the field of biomedical technology. Through proteomic analysis, ELISA assays, and immunohistochemical analysis of urinary proteins from prostate cancer patients, clear cell renal cell carcinoma patients, urothelial carcinoma patients, and healthy individuals, as well as paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue, urothelial carcinoma tissue, and clear cell renal cell carcinoma tissue, it was found that REEP6 and REEP5 proteins are related to the occurrence and development of prostate cancer and can be used to assist in the diagnosis of prostate cancer. Furthermore, in urinary testing, REEP6 and REEP5 have higher sensitivity compared to PSA, and the three proteins can complement each other, thus helping to improve the diagnostic rate and non-invasive screening capabilities. Research on the relationship between REEP6 and REEP5 proteins and prostate cancer facilitates non-invasive follow-up after treatment and guides medication, thereby improving survival rates.